Eli Lilly and Company $LLY Position Boosted by Synergy Asset Management LLC

Key Points

• Synergy Asset Management LLC increased its stake in Eli Lilly and Company by 554.1% during the 2nd quarter, owning 26,865 shares valued at approximately $20.94 million.
• The company's Q2 earnings beat expectations, reporting $6.31 earnings per share on revenue of $15.56 billion, a 37.6% increase year-over-year.
• Analysts have mixed ratings on the stock, with target prices ranging from $900.00 to $1,135.00, leading to a consensus average target price of $939.61.

Synergy Asset Management LLC lifted its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 554.1% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,865 shares of the company's stock after purchasing an additional 22,758 shares during the period. Eli Lilly and Company comprises about 2.4% of Synergy Asset Management LLC's investment portfolio, making the stock its 13th biggest holding. Synergy Asset Management LLC's holdings in Eli Lilly and Company were worth $20,942,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of LLY. Brighton Jones LLC lifted its position in shares of Eli Lilly and Company by 22.0% during the fourth quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after purchasing an additional 40 shares during the last quarter. Apella Capital LLC lifted its position in shares of Eli Lilly and Company by 9.4% during the first quarter. Apella Capital LLC now owns 1,749 shares of the company's stock worth $1,318,000 after purchasing an additional 151 shares during the last quarter. Iams Wealth Management LLC lifted its position in shares of Eli Lilly and Company by 13.9% during the first quarter. Iams Wealth Management LLC now owns 368 shares of the company's stock worth $304,000 after purchasing an additional 45 shares during the last quarter. Finally, Clare Market Investments LLC lifted its position in shares of Eli Lilly and Company by 90.8% during the first quarter. Clare Market Investments LLC now owns 4,209 shares of the company's stock worth $3,476,000 after purchasing an additional 2,003 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CEO David A. Ricks purchased 1,632 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were bought at an average price of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares in the company, valued at approximately $352,431,926.77. This represents a 0.30% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Daniel Skovronsky purchased 1,000 shares of the business's stock in a transaction dated Tuesday, August 12th. The shares were acquired at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the acquisition, the executive vice president owned 137,660 shares of the company's stock, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. Company insiders own 0.13% of the company's stock.

Eli Lilly and Company Stock Performance

LLY opened at $820.69 on Friday. The business's 50 day moving average is $734.03 and its 200-day moving average is $766.34. The stock has a market cap of $776.75 billion, a PE ratio of 53.64, a price-to-earnings-growth ratio of 1.15 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $937.00.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. The company had revenue of $15.56 billion for the quarter, compared to analysts' expectations of $14.40 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The business's revenue for the quarter was up 37.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.92 earnings per share. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. Morgan Stanley reissued an "overweight" rating and issued a $1,135.00 target price (up previously from $1,133.00) on shares of Eli Lilly and Company in a report on Thursday, July 10th. Deutsche Bank Aktiengesellschaft cut their target price on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a report on Saturday, September 20th. DZ Bank raised shares of Eli Lilly and Company from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 14th. Finally, JPMorgan Chase & Co. cut their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set an "overweight" rating on the stock in a report on Tuesday, September 16th. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and nine have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.